小肾肿物的主动监测与立即干预:成本效果与临床决策分析
本研究采用决策分析马尔可夫模型,针对65岁偶发小肾肿物患者比较主动监测(AS,可延迟干预)、立即部分肾切除、根治性肾切除和热消融4种策略的10年健康结局与成本。AS在10万美元/质量调整生命年阈值下最具成本效果,且当AS年转移进展概率足够低(多数年龄基线<0.35%-0.45%)时健康效用更高。
要点
- 在10万美元/质量调整生命年支付阈值下,AS是最具成本效果的管理策略。
- 10年全因死亡率:AS为22.6%,立即部分肾切除为21.9%,立即根治性肾切除为22.4%,立即热消融为23.7%。
- 当AS年转移进展概率足够低(多数年龄基线<0.35%-0.45%)时,AS可获得比其他策略更高的健康效用。
核心结论
- 与立即干预相比,AS联合适时延迟干预为小肾肿物患者提供了一种安全且具成本效果的管理方式。
- 对于转移潜能极低的肿瘤患者,AS可能带来比立即干预更好的患者结局。
研究设计与样本
- 研究采用决策分析马尔可夫模型,对象为65岁偶发小肾肿物患者,比较AS(可延迟干预)、立即部分肾切除、立即根治性肾切除和立即热消融4种策略。
- 评估指标包括死亡率、直接医疗成本、质量调整生命年和增量成本效果比,时间跨度为10年。
主要发现
- 10年全因死亡率:AS为22.6%,立即部分肾切除为21.9%,立即根治性肾切除为22.4%,立即热消融为23.7%。
- 在10万美元/质量调整生命年的支付阈值下,AS是最具成本效果的管理策略,且结果在单因素、多因素和概率敏感性分析中均稳健。
- 临床决策分析显示,肿瘤转移潜能、患者年龄、个人偏好和健康状况是影响最优管理策略的重要因素。
- 当AS年转移进展概率足够低(多数年龄基线<0.35%-0.45%,与<2 cm小肾肿物的典型转移潜能一致)时,AS可获得比其他策略更高的健康效用。
临床怎么用
- 作者认为,与立即干预相比,AS联合适时延迟干预是小肾肿物患者安全且具成本效果的管理方式。
- 作者认为,对于转移潜能极低的肿瘤患者,AS可能带来比立即干预更好的患者结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Active surveillance (AS) with the possibility of delayed intervention (DI) is emerging as a safe alternative to immediate intervention for many patients with small renal masses (SRMs). However, limited comparative data exist to inform the most appropriate management strategy for SRMs. MATERIALS AND METHODS: Decision analytic Markov modeling was performed to estimate the health outcomes and costs of 4 management strategies for 65-year-old patients with an incidental SRM: AS (with possible DI), immediate partial nephrectomy, radical nephrectomy, and thermal ablation. Mortality, direct medical costs, quality-adjusted life-years, and incremental cost-effectiveness ratios were evaluated over 10 years. RESULTS: The 10-year all-cause mortality was 22.6% for AS, 21.9% for immediate partial nephrectomy, 22.4% for immediate radical nephrectomy, and 23.7% for immediate thermal ablation. At a willingness-to-pay threshold of $100,000/quality-adjusted life-year, AS was the most cost-effective management strategy. The results were robust in univariate, multivariate, and probabilistic sensitivity analyses. Clinical decision analysis demonstrated that the tumor's metastatic potential, patient age, individual preferences, and health status were important factors influencing the optimal management strategy. Notably, if the annual probability of metastatic progression from AS was sufficiently low (under 0.35%-0.45% for most ages at baseline), consistent with the typical metastatic potential of SRMs <2 cm, AS would achieve higher health utilities than the other strategies. CONCLUSIONS: Compared to immediate intervention, AS with timely DI offers a safe and cost-effective approach to managing patients with SRMs. For patients harboring tumors of very low metastatic potential, AS may lead to better patient outcomes than immediate intervention.
引用
- Su ZT, Patel HD, Huang MM, et al. Active Surveillance versus Immediate Intervention for Small Renal Masses: A Cost-Effectiveness and Clinical Decision Analysis. J Urol. 2022. PMID: 35686837. doi:10.1097/JU.0000000000002812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。